Phio Pharmaceuticals (Phio Pharmaceuticals) Total Liabilities : $1.25 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Total Liabilities?

Phio Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $1.25 Mil.

Phio Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 ($2.33 Mil) to Dec. 2023 ($1.63 Mil) and declined from Dec. 2023 ($1.63 Mil) to Mar. 2024 ($1.25 Mil).

Phio Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 ($3.24 Mil) to Dec. 2022 ($1.98 Mil) and declined from Dec. 2022 ($1.98 Mil) to Dec. 2023 ($1.63 Mil).

Phio Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Phio Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Total Liabilities Chart

Phio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.29

2.72

3.24

1.98

1.63

Phio Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.40	2.39	2.33	1.63	1.25

Phio Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Phio Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.634	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.63

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	9.364	-	7.73
	=	1.63

Phio Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.249	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.25

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	6.853	-	5.604
	=	1.25

Phio Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581